Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory in triple negative breast cancer 2641

Abstract Description Objective This study investigates the role of transcription factor FOXM1 in creating an immune-suppressive tumor microenvironment (TME) by regulating stress ligands and the STING pathway in triple-negative breast cancer (TNBC). Methods We performed in vitro and in vivo assays using CRISPR/Cas9-mediated knockout of FOXM1 in TNBC cell lines and syngeneic mouse models. Using single-cell RNA sequencing, we analyzed the impact of tumor-intrinsic FOXM1 on stress ligand expression and its downstream effects on immune cell interactions. FOXM1’s epigenetic regulation on STING pathway was further validated through chromatin immunoprecipitation. Results We found tumor-intrinsic FOXM1 establishes an immune-suppressive TME by downregulating stress ligands like ULBP1 on cancer cells. This inhibition disrupts NKG2D-NKG2DL signaling, a key pathway for initiating natural killer and T cell cytotoxicity against cancer cells. FOXM1 achieves this by epigenetically silencing the DNA-sensor protein STING via a DNMT1-UHRF1 complex. Notably, patients with elevated FOXM1 and DNMT1 levels and reduced STING and ULBP1 levels show poorer survival rates and reduced responsiveness to immunotherapy. Conclusions Our findings identify FOXM1 as a key regulator of immune evasion in TNBC, revealing a new pathway by which it shapes the TME through epigenetic repression. Targeting FOXM1 or its downstream effectors could enhance immunotherapy efficacy, offering new therapeutic strategies for patients with TNBC. Funding Sources Supported by NIH NIGMS/T32GM113896; T32GM145432; T32CA279363; R01CA179120; R01CA239227; P30CA054174; CPRIT RP200110. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.538
Primary Topic
interferon and immune responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory in triple negative breast cancer 2641

Manjeet K. Rao, Jian Yu Huang, Santosh Timilsina
The Journal of Immunology
interferon and immune responses
article

Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory in triple negative breast cancer 2641

Manjeet K. Rao, Jian Yu Huang, Santosh Timilsina
article en

Abstract

Abstract Description Objective This study investigates the role of transcription factor FOXM1 in creating an immune-suppressive tumor microenvironment (TME) by regulating stress ligands and the STING pathway in triple-negative breast cancer (TNBC). Methods We performed in vitro and in vivo assays using CRISPR/Cas9-mediated knockout of FOXM1 in TNBC cell lines and syngeneic mouse models. Using single-cell RNA sequencing, we analyzed the impact of tumor-intrinsic FOXM1 on stress ligand expression and its downstream effects on immune cell interactions. FOXM1’s epigenetic regulation on STING pathway was further validated through chromatin immunoprecipitation. Results We found tumor-intrinsic FOXM1 establishes an immune-suppressive TME by downregulating stress ligands like ULBP1 on cancer cells. This inhibition disrupts NKG2D-NKG2DL signaling, a key pathway for initiating natural killer and T cell cytotoxicity against cancer cells. FOXM1 achieves this by epigenetically silencing the DNA-sensor protein STING via a DNMT1-UHRF1 complex. Notably, patients with elevated FOXM1 and DNMT1 levels and reduced STING and ULBP1 levels show poorer survival rates and reduced responsiveness to immunotherapy. Conclusions Our findings identify FOXM1 as a key regulator of immune evasion in TNBC, revealing a new pathway by which it shapes the TME through epigenetic repression. Targeting FOXM1 or its downstream effectors could enhance immunotherapy efficacy, offering new therapeutic strategies for patients with TNBC. Funding Sources Supported by NIH NIGMS/T32GM113896; T32GM145432; T32CA279363; R01CA179120; R01CA239227; P30CA054174; CPRIT RP200110. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

The Journal of ImmunologyVol. 214(Supplement_1)
The University of Texas at San Antonio Health Science Center (US)
Openalex Percentile: Top 61%
interferon and immune responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.